Search

Your search keyword '"Janjigian, Yelena"' showing total 902 results
Start Over Author "Janjigian, Yelena"
902 results on '"Janjigian, Yelena"'

2. Clinical practice guidelines for esophagogastric junction cancer: Upper GI Oncology Summit 2023

Author

Kitagawa, Yuko, Matsuda, Satoru, Gotoda, Takuji, Kato, Ken, Wijnhoven, Bas, Lordick, Florian, Bhandari, Pradeep, Kawakubo, Hirofumi, Kodera, Yasuhiro, Terashima, Masanori, Muro, Kei, Takeuchi, Hiroya, Mansfield, Paul F., Kurokawa, Yukinori, So, Jimmy, Mönig, Stefan Paul, Shitara, Kohei, Rha, Sun Young, Janjigian, Yelena, Takahari, Daisuke, Chau, Ian, Sharma, Prateek, Ji, Jiafu, de Manzoni, Giovanni, Nilsson, Magnus, Kassab, Paulo, Hofstetter, Wayne L., Smyth, Elizabeth Catherine, Lorenzen, Sylvie, Doki, Yuichiro, Law, Simon, Oh, Do-Youn, Ho, Khek Yu, Koike, Tomoyuki, Shen, Lin, van Hillegersberg, Richard, Kawakami, Hisato, Xu, Rui-Hua, Wainberg, Zev, Yahagi, Naohisa, Lee, Yeong Yeh, Singh, Rajvinder, Ryu, Min-Hee, Ishihara, Ryu, Xiao, Zili, Kusano, Chika, Grabsch, Heike Irmgard, Hara, Hiroki, Mukaisho, Ken-ichi, Makino, Tomoki, Kanda, Mitsuro, Booka, Eisuke, Suzuki, Sho, Hatta, Waku, Kato, Motohiko, Maekawa, Akira, Kawazoe, Akihito, Yamamoto, Shun, Nakayama, Izuma, Narita, Yukiya, Yang, Han-Kwang, Yoshida, Masahiro, and Sano, Takeshi

Published
2024
Full Text
View/download PDF

3. Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study.

Author

Van Cutsem, Eric, di Bartolomeo, Maria, Smyth, Elizabeth, Chau, Ian, Park, Haeseong, Siena, Salvatore, Lonardi, Sara, Wainberg, Zev, Ajani, Jaffer, Chao, Joseph, Janjigian, Yelena, Qin, Amy, Singh, Jasmeet, Barlaskar, Ferdous, Kawaguchi, Yoshinori, and Ku, Geoffrey

Subjects
Female, Humans, Male, Middle Aged, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Disease Progression, Esophageal Neoplasms, Esophagogastric Junction, Immunoconjugates, Receptor, ErbB-2, Stomach Neoplasms, Trastuzumab, Aged
Abstract

BACKGROUND: Approximately 15-20% of advanced gastric and gastro-oesophageal junction cancers overexpress HER2. In DESTINY-Gastric01, the HER2-targeted antibody-drug conjugate trastuzumab deruxtecan improved response and overall survival versus chemotherapy in patients from Japan and South Korea with locally advanced or metastatic HER2-positive gastric or gastro-oesophageal junction cancer whose disease progressed after two lines of previous therapy including trastuzumab. Here, we report primary and updated analyses of the single-arm, phase 2 DESTINY-Gastric02 trial, which aimed to examine trastuzumab deruxtecan in patients living in the USA and Europe. METHODS: DESTINY-Gastric02 is a single-arm, phase 2 study in adult patients from 24 study sites in the USA and Europe (Belgium, Spain, Italy, and the UK). Eligible patients were aged at least 18 years and had an Eastern Cooperative Oncology Group performance status of 0 or 1, pathologically documented unresectable or metastatic gastric or gastro-oesophageal junction cancer, progressive disease on or after first-line therapy with a trastuzumab-containing regimen, with at least one measurable lesion per Response Evaluation Criteria in Solid Tumours (version 1.1), and centrally confirmed HER2-positive disease on a postprogression biopsy. Patients were given 6·4 mg/kg of trastuzumab deruxtecan intravenously every 3 weeks until disease progression, withdrawal by patient, physician decision, or death. The primary endpoint was confirmed objective response rate by independent central review. The primary endpoint and safety were assessed in the full analysis set (ie, participants who received at least one dose of study drug). Here, we report the primary analysis of this study, with a data cutoff of April 9, 2021, and an updated analysis, with a data cutoff of Nov 8, 2021. This trial is registered with ClinicalTrials.gov, NCT04014075, and is ongoing. FINDINGS: Between Nov 26, 2019, and Dec 2, 2020, 89 patients were screened and 79 were enrolled and subsequently treated with trastuzumab deruxtecan (median age 60·7 years [IQR 52·0-68·3], 57 [72%] of 79 were male, 22 [28%] were female, 69 [87%] were White, four [5%] were Asian, one [1%] was Black or African American, one [1%] was Native Hawaiian or Pacific Islander, one had missing race, and three [4%] were other races). At the primary analysis (median follow-up 5·9 months [IQR 4·6-8·6 months]), confirmed objective response was reported in 30 (38% [95% CI 27·3-49·6]) of 79 patients, including three (4%) complete responses and 27 (34%) partial responses, as assessed by independent central review. As of data cutoff for the updated analysis (median follow-up 10·2 months [IQR 5·6-12·9]), a confirmed objective response was reported in 33 (42% [95% CI 30·8-53·4]) of 79 patients, including four (5%) complete responses and 29 (37%) partial responses, as assessed by independent central review. The most common grade 3 or worse treatment-emergent adverse events were anaemia (11 [14%]), nausea (six [8%]), decreased neutrophil count (six [8%]), and decreased white blood cell count (five [6%]). Drug-related serious treatment-emergent adverse events occurred in ten patients (13%). Deaths determined to be associated with study treatment occurred in two patients (3%) and were due to interstitial lung disease or pneumonitis. INTERPRETATION: These clinically meaningful results support the use of trastuzumab deruxtecan as second-line therapy in patients with HER2-positive advanced gastric or gastro-oesophageal junction cancer. FUNDING: Daiichi Sankyo and AstraZeneca.

Published
2023

5. Neoplasia risk in patients with Lynch syndrome treated with immune checkpoint blockade

Author

Harrold, Emily C., Foote, Michael B., Rousseau, Benoit, Walch, Henry, Kemel, Yelena, Richards, Allison L., Keane, Fergus, Cercek, Andrea, Yaeger, Rona, Rathkopf, Dana, Segal, Neil H., Patel, Zalak, Maio, Anna, Borio, Matilde, O’Reilly, Eileen M., Reidy, Diane, Desai, Avni, Janjigian, Yelena Y., Murciano-Goroff, Yonina R., Carlo, Maria I., Latham, Alicia, Liu, Ying L., Walsh, Michael F., Ilson, David, Rosenberg, Jonathan E., Markowitz, Arnold J., Weiser, Martin R., Rossi, Anthony M., Vanderbilt, Chad, Mandelker, Diana, Bandlamudi, Chaitanya, Offit, Kenneth, Berger, Michael F., Solit, David B., Saltz, Leonard, Shia, Jinru, Diaz, Jr., Luis A., and Stadler, Zsofia K.

Published
2023
Full Text
View/download PDF

6. Epidermal Growth Factor Receptor Inhibition in Epidermal Growth Factor Receptor-Amplified Gastroesophageal Cancer: Retrospective Global Experience.

Author

Maron, Steven, Moya, Stephanie, Morano, Federica, Emmett, Matthew, Chou, Joanne, Sabwa, Shalom, Walch, Henry, Peterson, Bryan, Schrock, Alexa, Zhang, Liangliang, Janjigian, Yelena, Chalasani, Sree, Ku, Geoffrey, Disel, Umut, Enzinger, Peter, Uboha, Nataliya, Kato, Shumei, Yoshino, Takayuki, Shitara, Kohei, Nakamura, Yoshiaki, Saeed, Anwaar, Kasi, Pashtoon, Chao, Joseph, Lee, Jeeyun, Capanu, Marinela, Petty, Russell, Pietrantonio, Filippo, Klempner, Samuel, Catenacci, Daniel, and Wainberg, Zev

Subjects
Adenocarcinoma, Antibodies, Bispecific, ErbB Receptors, Esophageal Neoplasms, Humans, In Situ Hybridization, Fluorescence, Retrospective Studies, Stomach Neoplasms
Abstract

PURPOSE: Subset analyses from phase III evaluation of epidermal growth factor receptor inhibition (EGFRi) suggest improved outcomes in patients with EGFR-amplified gastroesophageal adenocarcinoma (GEA), but large-scale analyses are lacking. This multi-institutional analysis sought to determine the role of EGFRi in the largest cohort of patients with EGFR-amplified GEA to date. PATIENTS AND METHODS: A total of 60 patients from 15 tertiary cancer centers in six countries met the inclusion criteria. These criteria required histologically confirmed GEA in the metastatic or unresectable setting with EGFR amplification identified by using a Clinical Laboratory Improvement Amendments-approved assay, and who received on- or off-protocol EGFRi. Testing could be by tissue next-generation sequencing, plasma circulating tumor DNA next-generation sequencing, and/or fluorescence in situ hybridization performed by a Clinical Laboratory Improvement Amendments approved laboratory. Treatment patterns and outcomes analysis was also performed using a deidentified clinicogenomic database (CGDB). RESULTS: Sixty patients with EGFR-amplified GEA received EGFRi, including 31 of 60 patients (52%) with concurrent chemotherapy. Across treatment lines, patients achieved a 43% objective response rate with a median progression-free survival of 4.6 months (95% CI, 3.5 to 6.4). Patients receiving EGFRi in first-, second-, and third-line therapy achieved a median overall survival of 20.6 months (95% CI, 13.5 to not reached [NR]), 9 months (95% CI, 7.9 to NR), and 8.4 months (7.6 to NR), respectively. This survival far exceeded the 11.2-month (95% CI, 8.7 to 14.2) median overall survival from first-line initiation of non-EGFRi therapy in patients with EGFR-amplified GEA in the CGDB. Despite this benefit, analysis of the CGDB (January 2011-December 2020) suggests that only 5% of patients with EGFR-amplified GEA received EGFRi. CONCLUSION: Patients with EGFR-amplified GEA derive significant benefit from EGFRi. Further prospective investigation of EGFRi in a well-selected patient population is ongoing in an upcoming trial of amivantamab in EGFR and/or MET amplified GEA.

Published
2022

9. Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study

Author

Shitara, Kohei, Rha, Sun Young, Wyrwicz, Lucjan S, Oshima, Takashi, Karaseva, Nina, Osipov, Mikhail, Yasui, Hisateru, Yabusaki, Hiroshi, Afanasyev, Sergey, Park, Young-Kyu, Al-Batran, Salah-Eddin, Yoshikawa, Takaki, Yanez, Patricio, Di Bartolomeo, Maria, Lonardi, Sara, Tabernero, Josep, Van Cutsem, Eric, Janjigian, Yelena Y, Oh, Do-Youn, Xu, Jianming, Fang, Xiao, Shih, Chie-Schin, Bhagia, Pooja, and Bang, Yung-Jue

Published
2024
Full Text
View/download PDF

10. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial

Author

Janjigian, Yelena Y, Kawazoe, Akihito, Bai, Yuxian, Xu, Jianming, Lonardi, Sara, Metges, Jean Phillipe, Yanez, Patricio, Wyrwicz, Lucjan S, Shen, Lin, Ostapenko, Yuriy, Bilici, Mehmet, Chung, Hyun Cheol, Shitara, Kohei, Qin, Shu-Kui, Van Cutsem, Eric, Tabernero, Josep, Li, Kan, Shih, Chie-Schin, Bhagia, Pooja, and Rha, Sun Young

Published
2023
Full Text
View/download PDF

11. First-line regorafenib with nivolumab and chemotherapy in advanced oesophageal, gastric, or gastro-oesophageal junction cancer in the USA: a single-arm, single-centre, phase 2 trial

Author

Cytryn, Samuel L, Moy, Ryan H, Cowzer, Darren, Shah, Ronak H, Chou, Joanne F, Joshi, Smita S, Ku, Geoffrey Y, Maron, Steven B, Desai, Avni, Yang, Jessica, Sugarman, Ryan, Rao, Devika, Goldberg, Zoe, Charalambous, Carmelina, Lapshina, Maria, Antoine, Ariel, Socolow, Fiona, Trivedi, Nikhil, Capanu, Marinela, Gerdes, Hans, Schattner, Mark A, Simmons, Marc, Lacouture, Mario E, Paroder, Viktoriya, Tang, Laura H, Shia, Jinru, Ilson, David H, Solit, David B, Berger, Michael F, and Janjigian, Yelena Y

Published
2023
Full Text
View/download PDF

12. PCK1 and DHODH drive colorectal cancer liver metastatic colonization and hypoxic growth by promoting nucleotide synthesis.

Author

Yamaguchi, Norihiro, Weinberg, Ethan M, Nguyen, Alexander, Liberti, Maria V, Goodarzi, Hani, Janjigian, Yelena Y, Paty, Philip B, Saltz, Leonard B, Kingham, T Peter, Loo, Jia Min, de Stanchina, Elisa, and Tavazoie, Sohail F

Subjects
Animals, Humans, Mice, Colorectal Neoplasms, Liver Neoplasms, Disease Models, Animal, Phosphoenolpyruvate Carboxykinase (GTP), Oxidoreductases Acting on CH-CH Group Donors, Nucleotides, Intracellular Signaling Peptides and Proteins, Cell Survival, Models, Theoretical, Heterografts, Hypoxia, cancer biology, cancer metabolism, cancer metastasis, human, human biology, medicine, mouse, Disease Models, Animal, Models, Theoretical, Phosphoenolpyruvate Carboxykinase, Biochemistry and Cell Biology
Abstract

Colorectal cancer (CRC) is a major cause of human death. Mortality is primarily due to metastatic organ colonization, with the liver being the main organ affected. We modeled metastatic CRC (mCRC) liver colonization using patient-derived primary and metastatic tumor xenografts (PDX). Such PDX modeling predicted patient survival outcomes. In vivo selection of multiple PDXs for enhanced metastatic colonization capacity upregulated the gluconeogenic enzyme PCK1, which enhanced liver metastatic growth by driving pyrimidine nucleotide biosynthesis under hypoxia. Consistently, highly metastatic tumors upregulated multiple pyrimidine biosynthesis intermediary metabolites. Therapeutic inhibition of the pyrimidine biosynthetic enzyme DHODH with leflunomide substantially impaired CRC liver metastatic colonization and hypoxic growth. Our findings provide a potential mechanistic basis for the epidemiologic association of anti-gluconeogenic drugs with improved CRC metastasis outcomes, reveal the exploitation of a gluconeogenesis enzyme for pyrimidine biosynthesis under hypoxia, and implicate DHODH and PCK1 as metabolic therapeutic targets in CRC metastatic progression.

Published
2019

13. Durvalumab and PET-Directed Chemoradiation in Locally Advanced Esophageal Adenocarcinoma: A Phase Ib/II Study

Author

Cowzer, Darren, Wu, Abraham Jing-Ching, Sihag, Smita, Walch, Henry S., Park, Bernard J., Jones, David R., Gu, Ping, Maron, Steven B., Sugarman, Ryan, Chalasani, Sree Bhavani, Shcherba, Marina, Capanu, Marinela, Chou, Joanne F., Choe, Jennie K., Nosov, Anton, Adusumilli, Prasad S., Yeh, Randy, Tang, Laura H., Ilson, David H., Janjigian, Yelena Y., Molena, Daniela, and Ku, Geoffrey Y.

Published
2023
Full Text
View/download PDF

14. Genomic Landscape of Adenocarcinomas Across the Gastroesophageal Junction

Author

Nakauchi, Masaya, primary, Walch, Henry S., additional, Nussenzweig, Samuel, additional, Carr, Rebecca, additional, Vos, Elvira, additional, Berger, Michael F., additional, Schultz, Nikolaus, additional, Janjigian, Yelena, additional, Wu, Abraham, additional, Tang, Laura, additional, Shah, Pari, additional, Jones, David R., additional, Coit, Dan, additional, Strong, Vivian E., additional, Molena, Daniela, additional, and Sihag, Smita, additional

Published
2024
Full Text
View/download PDF

16. Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer

Author

Shitara, Kohei, Ajani, Jaffer A., Moehler, Markus, Garrido, Marcelo, Gallardo, Carlos, Shen, Lin, Yamaguchi, Kensei, Wyrwicz, Lucjan, Skoczylas, Tomasz, Bragagnoli, Arinilda Campos, Liu, Tianshu, Tehfe, Mustapha, Elimova, Elena, Bruges, Ricardo, Zander, Thomas, de Azevedo, Sergio, Kowalyszyn, Ruben, Pazo-Cid, Roberto, Schenker, Michael, Cleary, James M., Yanez, Patricio, Feeney, Kynan, Karamouzis, Michalis V., Poulart, Valerie, Lei, Ming, Xiao, Hong, Kondo, Kaoru, Li, Mingshun, and Janjigian, Yelena Y.

Published
2022
Full Text
View/download PDF

19. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer

Author

Janjigian, Yelena Y., Kawazoe, Akihito, Yañez, Patricio, Li, Ning, Lonardi, Sara, Kolesnik, Oleksii, and Barajas, Olga

Subjects
Stomach cancer -- Diagnosis -- Care and treatment, Chemotherapy -- Testing, Cancer -- Chemotherapy, Environmental issues, Science and technology, Zoology and wildlife conservation
Abstract

Human epidermal growth factor receptor 2 (HER2, also known as ERBB2) amplification or overexpression occurs in approximately 20% of advanced gastric or gastro-oesophageal junction adenocarcinomas.sup.1-3. More than a decade ago, combination therapy with the anti-HER2 antibody trastuzumab and chemotherapy became the standard first-line treatment for patients with these types of tumours.sup.4. Although adding the anti-programmed death 1 (PD-1) antibody pembrolizumab to chemotherapy does not significantly improve efficacy in advanced HER2-negative gastric cancer.sup.5, there are preclinical.sup.6-19 and clinical.sup.20,21 rationales for adding pembrolizumab in HER2-positive disease. Here we describe results of the protocol-specified first interim analysis of the randomized, double-blind, placebo-controlled phase III KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for unresectable or metastatic, HER2-positive gastric or gastro-oesophageal junction adenocarcinoma.sup.22 (https://clinicaltrials.gov, NCT03615326). We show that adding pembrolizumab to trastuzumab and chemotherapy markedly reduces tumour size, induces complete responses in some participants, and significantly improves objective response rate. Interim analysis of a phase III clinical trial of HER2-positive gastric adenocarinoma shows pembrolizumab plus trastuzumab and chemotherapy improves response rates compared with trastuzumab and chemotherapy alone., Author(s): Yelena Y. Janjigian [sup.1] , Akihito Kawazoe [sup.2] , Patricio Yañez [sup.3] , Ning Li [sup.4] , Sara Lonardi [sup.5] , Oleksii Kolesnik [sup.6] , Olga Barajas [sup.7] , [...]

Published
2021
Full Text
View/download PDF

21. Waiting to Operate: The Risk of Salvage Esophagectomy

Author

Boerner, Thomas, Harrington, Caitlin, Tan, Kay See, Adusumilli, Prasad S., Bains, Manjit S., Bott, Matthew J., Downey, Robert J., Huang, James, Ilson, David H., Isbell, James M., Janjigian, Yelena Y., Park, Bernard J., Rocco, Gaetano, Rusch, Valerie W., Sihag, Smita, Wu, Abraham J., Jones, David R., and Molena, Daniela

Published
2023
Full Text
View/download PDF

27. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial

Author

Janjigian, Yelena Y, Shitara, Kohei, Moehler, Markus, Garrido, Marcelo, Salman, Pamela, Shen, Lin, Wyrwicz, Lucjan, Yamaguchi, Kensei, Skoczylas, Tomasz, Campos Bragagnoli, Arinilda, Liu, Tianshu, Schenker, Michael, Yanez, Patricio, Tehfe, Mustapha, Kowalyszyn, Ruben, Karamouzis, Michalis V, Bruges, Ricardo, Zander, Thomas, Pazo-Cid, Roberto, Hitre, Erika, Feeney, Kynan, Cleary, James M, Poulart, Valerie, Cullen, Dana, Lei, Ming, Xiao, Hong, Kondo, Kaoru, Li, Mingshun, and Ajani, Jaffer A

Published
2021
Full Text
View/download PDF

30. Clinical practice guidelines for esophagogastric junction cancer: Upper GI Oncology Summit 2023

Author

MS CGO, Cancer, Kitagawa, Yuko, Matsuda, Satoru, Gotoda, Takuji, Kato, Ken, Wijnhoven, Bas, Lordick, Florian, Bhandari, Pradeep, Kawakubo, Hirofumi, Kodera, Yasuhiro, Terashima, Masanori, Muro, Kei, Takeuchi, Hiroya, Mansfield, Paul F., Kurokawa, Yukinori, So, Jimmy, Mönig, Stefan Paul, Shitara, Kohei, Rha, Sun Young, Janjigian, Yelena, Takahari, Daisuke, Chau, Ian, Sharma, Prateek, Ji, Jiafu, de Manzoni, Giovanni, Nilsson, Magnus, Kassab, Paulo, Hofstetter, Wayne L., Smyth, Elizabeth Catherine, Lorenzen, Sylvie, Doki, Yuichiro, Law, Simon, Oh, Do Youn, Ho, Khek Yu, Koike, Tomoyuki, Shen, Lin, van Hillegersberg, Richard, Kawakami, Hisato, Xu, Rui Hua, Wainberg, Zev, Yahagi, Naohisa, Lee, Yeong Yeh, Singh, Rajvinder, Ryu, Min Hee, Ishihara, Ryu, Xiao, Zili, Kusano, Chika, Grabsch, Heike Irmgard, Hara, Hiroki, Mukaisho, Ken Ichi, Makino, Tomoki, Kanda, Mitsuro, Booka, Eisuke, Suzuki, Sho, Hatta, Waku, Kato, Motohiko, Maekawa, Akira, Kawazoe, Akihito, Yamamoto, Shun, Nakayama, Izuma, Narita, Yukiya, Yang, Han Kwang, Yoshida, Masahiro, Sano, Takeshi, MS CGO, Cancer, Kitagawa, Yuko, Matsuda, Satoru, Gotoda, Takuji, Kato, Ken, Wijnhoven, Bas, Lordick, Florian, Bhandari, Pradeep, Kawakubo, Hirofumi, Kodera, Yasuhiro, Terashima, Masanori, Muro, Kei, Takeuchi, Hiroya, Mansfield, Paul F., Kurokawa, Yukinori, So, Jimmy, Mönig, Stefan Paul, Shitara, Kohei, Rha, Sun Young, Janjigian, Yelena, Takahari, Daisuke, Chau, Ian, Sharma, Prateek, Ji, Jiafu, de Manzoni, Giovanni, Nilsson, Magnus, Kassab, Paulo, Hofstetter, Wayne L., Smyth, Elizabeth Catherine, Lorenzen, Sylvie, Doki, Yuichiro, Law, Simon, Oh, Do Youn, Ho, Khek Yu, Koike, Tomoyuki, Shen, Lin, van Hillegersberg, Richard, Kawakami, Hisato, Xu, Rui Hua, Wainberg, Zev, Yahagi, Naohisa, Lee, Yeong Yeh, Singh, Rajvinder, Ryu, Min Hee, Ishihara, Ryu, Xiao, Zili, Kusano, Chika, Grabsch, Heike Irmgard, Hara, Hiroki, Mukaisho, Ken Ichi, Makino, Tomoki, Kanda, Mitsuro, Booka, Eisuke, Suzuki, Sho, Hatta, Waku, Kato, Motohiko, Maekawa, Akira, Kawazoe, Akihito, Yamamoto, Shun, Nakayama, Izuma, Narita, Yukiya, Yang, Han Kwang, Yoshida, Masahiro, and Sano, Takeshi

Published
2024

31. Clinical practice guidelines for esophagogastric junction cancer:Upper GI Oncology Summit 2023

Author

Kitagawa, Yuko, Matsuda, Satoru, Gotoda, Takuji, Kato, Ken, Wijnhoven, Bas, Lordick, Florian, Bhandari, Pradeep, Kawakubo, Hirofumi, Kodera, Yasuhiro, Terashima, Masanori, Muro, Kei, Takeuchi, Hiroya, Mansfield, Paul F., Kurokawa, Yukinori, So, Jimmy, Mönig, Stefan Paul, Shitara, Kohei, Rha, Sun Young, Janjigian, Yelena, Takahari, Daisuke, Chau, Ian, Sharma, Prateek, Ji, Jiafu, de Manzoni, Giovanni, Nilsson, Magnus, Kassab, Paulo, Hofstetter, Wayne L., Smyth, Elizabeth Catherine, Lorenzen, Sylvie, Doki, Yuichiro, Law, Simon, Oh, Do Youn, Ho, Khek Yu, Koike, Tomoyuki, Shen, Lin, van Hillegersberg, Richard, Kawakami, Hisato, Xu, Rui Hua, Wainberg, Zev, Yahagi, Naohisa, Lee, Yeong Yeh, Singh, Rajvinder, Ryu, Min Hee, Ishihara, Ryu, Xiao, Zili, Kusano, Chika, Grabsch, Heike Irmgard, Hara, Hiroki, Mukaisho, Ken Ichi, Makino, Tomoki, Kanda, Mitsuro, Booka, Eisuke, Suzuki, Sho, Hatta, Waku, Kato, Motohiko, Maekawa, Akira, Kawazoe, Akihito, Yamamoto, Shun, Nakayama, Izuma, Narita, Yukiya, Yang, Han Kwang, Yoshida, Masahiro, Sano, Takeshi, Kitagawa, Yuko, Matsuda, Satoru, Gotoda, Takuji, Kato, Ken, Wijnhoven, Bas, Lordick, Florian, Bhandari, Pradeep, Kawakubo, Hirofumi, Kodera, Yasuhiro, Terashima, Masanori, Muro, Kei, Takeuchi, Hiroya, Mansfield, Paul F., Kurokawa, Yukinori, So, Jimmy, Mönig, Stefan Paul, Shitara, Kohei, Rha, Sun Young, Janjigian, Yelena, Takahari, Daisuke, Chau, Ian, Sharma, Prateek, Ji, Jiafu, de Manzoni, Giovanni, Nilsson, Magnus, Kassab, Paulo, Hofstetter, Wayne L., Smyth, Elizabeth Catherine, Lorenzen, Sylvie, Doki, Yuichiro, Law, Simon, Oh, Do Youn, Ho, Khek Yu, Koike, Tomoyuki, Shen, Lin, van Hillegersberg, Richard, Kawakami, Hisato, Xu, Rui Hua, Wainberg, Zev, Yahagi, Naohisa, Lee, Yeong Yeh, Singh, Rajvinder, Ryu, Min Hee, Ishihara, Ryu, Xiao, Zili, Kusano, Chika, Grabsch, Heike Irmgard, Hara, Hiroki, Mukaisho, Ken Ichi, Makino, Tomoki, Kanda, Mitsuro, Booka, Eisuke, Suzuki, Sho, Hatta, Waku, Kato, Motohiko, Maekawa, Akira, Kawazoe, Akihito, Yamamoto, Shun, Nakayama, Izuma, Narita, Yukiya, Yang, Han Kwang, Yoshida, Masahiro, and Sano, Takeshi

Published
2024

33. First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial.

Author

Janjigian, Yelena Y., Ajani, Jaffer A., Moehler, Markus, Shen, Lin, Garrido, Marcelo, Gallardo, Carlos, Wyrwicz, Lucjan, Yamaguchi, Kensei, Cleary, James M., Elimova, Elena, Karamouzis, Michalis, Bruges, Ricardo, Skoczylas, Tomasz, Bragagnoli, Arinilda, Liu, Tianshi, Tehfe, Mustapha, Zander, Thomas, Kowalyszyn, Ruben, Pazo-Cid, Roberto, and Schenker, Michael

Published
2024
Full Text
View/download PDF

34. First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial

Author

Janjigian, Yelena Y, Maron, Steven B, Chatila, Walid K, Millang, Brittanie, Chavan, Shweta S, Alterman, Carly, Chou, Joanne F, Segal, Michal F, Simmons, Marc Z, Momtaz, Parisa, Shcherba, Marina, Ku, Geoffrey Y, Zervoudakis, Alice, Won, Elizabeth S, Kelsen, David P, Ilson, David H, Nagy, Rebecca J, Lanman, Richard B, Ptashkin, Ryan N, Donoghue, Mark T A, Capanu, Marinela, Taylor, Barry S, Solit, David B, Schultz, Nikolaus, and Hechtman, Jaclyn F

Published
2020
Full Text
View/download PDF

35. Health-related quality of life (HRQOL) with pembrolizumab (pembro) plus trastuzumab (tras) and chemotherapy (chemo) in first-line HER2-positive (HER2+) advanced gastric cancer: KEYNOTE-811 trial results.

Author

Janjigian, Yelena Y., primary, Kawazoe, Akihito, additional, Xu, Jianming, additional, Lonardi, Sara, additional, Metges, Jean-Philippe, additional, Wyrwicz, Lucjan S., additional, Shen, Lin, additional, Ostapenko, Yuriy, additional, Bilici, Mehmet, additional, Lowery, Maeve Aine, additional, Valderrama, Adriana, additional, Guan, Yanfen, additional, Li, Kan, additional, Shih, Chie-Schin, additional, and Rha, Sun Young, additional

Published
2024
Full Text
View/download PDF

37. BRAF variants and oncogenic fusions to define sporadic MMR-deficient colorectal cancer subtypes.

Author

Abdelfattah, Somer, primary, Harada, Guilherme, additional, Patel, Shrey, additional, Artz, Oliver, additional, Yaeger, Rona, additional, Johannet, Paul, additional, Harrold, Emily, additional, Walch, Henry S., additional, Argiles, Guillem, additional, Rousseau, Benoit, additional, Stadler, Zsofia Kinga, additional, Cercek, Andrea, additional, Janjigian, Yelena Y., additional, Drilon, Alexander E., additional, Diaz, Luis A., additional, and Foote, Michael Bonner, additional

Published
2024
Full Text
View/download PDF

38. Phase 1b/II study of durvalumab (D) and tremelimumab (T) plus PET-adjudicated chemoradiation (CRT) in patients (Pts) with esophageal adenocarcinoma.

Author

Ku, Geoffrey Yuyat, primary, Wu, Abraham Jing-Ching, additional, Trivedi, Nikhil, additional, Maron, Steven Brad, additional, Joshi, Smita Suhas, additional, Ilson, David H., additional, Janjigian, Yelena Y., additional, Shcherba, Marina, additional, Li, Jia, additional, Tang, Laura H., additional, Yeh, Randy, additional, Sihag, Smita, additional, Park, Bernard J., additional, Jones, David Randolph, additional, and Molena, Daniela, additional

Published
2024
Full Text
View/download PDF

39. Pathological complete response (pCR) to 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) with or without durvalumab (D) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Subgroup analysis by region from the phase 3, randomized, double-blind MATTERHORN study.

Author

Janjigian, Yelena Y., primary, Al-Batran, Salah-Eddin, additional, Wainberg, Zev A., additional, Van Cutsem, Eric, additional, Molena, Daniela, additional, Muro, Kei, additional, Hyung, Woo Jin, additional, Wyrwicz, Lucjan S., additional, Oh, Do-Youn, additional, Omori, Takeshi, additional, Moehler, Markus, additional, Garrido, Marcelo, additional, Oliveira, Sulene CS, additional, Liberman, Moishe, additional, Castro Oliden, Victor, additional, Bilici, Mehmet, additional, Kurland, John F., additional, Xynos, Ioannis, additional, Mann, Helen, additional, and Tabernero, Josep, additional

Published
2024
Full Text
View/download PDF

40. Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 4 year (yr) follow-up of CheckMate 649.

Author

Shitara, Kohei, primary, Moehler, Markus H., additional, Ajani, Jaffer A., additional, Shen, Lin, additional, Garrido, Marcelo, additional, Gallardo, Carlos, additional, Wyrwicz, Lucjan S., additional, Yamaguchi, Kensei, additional, Cleary, James M., additional, Elimova, Elena, additional, Bruges Maya, Ricardo Elias, additional, Karamouzis, Michalis, additional, Skoczylas, Tomasz, additional, Bragagnoli, Arinilda, additional, Liu, Tianshu, additional, Tehfe, Mustapha, additional, Feeney, Kynan, additional, Wang, Rui, additional, Nathani, Raheel, additional, and Janjigian, Yelena Y., additional

Published
2024
Full Text
View/download PDF

41. Health-Related Quality of Life With Nivolumab Plus Chemotherapy Versus Chemotherapy in Patients With Advanced Gastric/Gastroesophageal Junction Cancer or Esophageal Adenocarcinoma From CheckMate 649

Author

Moehler, Markus, primary, Xiao, Hong, additional, Blum, Steven I., additional, Elimova, Elena, additional, Cella, David, additional, Shitara, Kohei, additional, Ajani, Jaffer A., additional, Janjigian, Yelena Y., additional, Garrido, Marcelo, additional, Shen, Lin, additional, Yamaguchi, Kensei, additional, Liu, Tianshu, additional, Schenker, Michael, additional, Kowalyszyn, Ruben, additional, Bragagnoli, Arinilda Campos, additional, Bruges, Ricardo, additional, Montesarchio, Vincenzo, additional, Pazo-Cid, Roberto, additional, Hunter, Shannon, additional, Davenport, Eric, additional, Wang, Jinyi, additional, Kondo, Kaoru, additional, Li, Mingshun, additional, and Wyrwicz, Lucjan, additional

Published
2023
Full Text
View/download PDF

42. Pembrolizumab in HER2-Positive Gastric Cancer.

Author

Janjigian, Yelena Y. and Sun Young Rha

Subjects
*EPIDERMAL growth factor receptors, *ESOPHAGOGASTRIC junction, *WATCHFUL waiting, *RADICAL prostatectomy, *SIMULATED patients
Abstract

The article published in the New England Journal of Medicine discusses the results of the KEYNOTE-811 trial, which evaluated the addition of pembrolizumab to trastuzumab and chemotherapy as a first-line treatment for HER2-positive gastric or gastroesophageal junction adenocarcinoma. The study found that adding pembrolizumab led to significantly longer overall survival compared to trastuzumab and chemotherapy alone, particularly in patients with a programmed death ligand 1 (PD-L1) combined positive score of 1 or more. The trial demonstrated a significant improvement in overall survival with pembrolizumab, with a median overall survival of 20.0 months compared to 16.8 months with placebo. [Extracted from the article]

Published
2024
Full Text
View/download PDF

43. Pharmacologically controlling protein-protein interactions through epichaperomes for therapeutic vulnerability in cancer

Author

Joshi, Suhasini, Gomes, Erica DaGama, Wang, Tai, Corben, Adriana, Taldone, Tony, Gandu, Srinivasa, Xu, Chao, Sharma, Sahil, Buddaseth, Salma, Yan, Pengrong, Chan, Lon Yin L., Gokce, Askan, Rajasekhar, Vinagolu K., Shrestha, Lisa, Panchal, Palak, Almodovar, Justina, Digwal, Chander S., Rodina, Anna, Merugu, Swathi, Pillarsetty, NagaVaraKishore, Miclea, Vlad, Peter, Radu I., Wang, Wanyan, Ginsberg, Stephen D., Tang, Laura, Mattar, Marissa, de Stanchina, Elisa, Yu, Kenneth H., Lowery, Maeve, Grbovic-Huezo, Olivera, O’Reilly, Eileen M., Janjigian, Yelena, Healey, John H., Jarnagin, William R., Allen, Peter J., Sander, Chris, Erdjument-Bromage, Hediye, Neubert, Thomas A., Leach, Steven D., and Chiosis, Gabriela

Published
2021
Full Text
View/download PDF

49. Patient metabolic profile defined by liver and muscle 18F-FDG PET avidity is independently associated with overall survival in gastric cancer.

Author

Vitiello, Gerardo A., Jayaprakasam, Vetri Sudar, Tang, Laura H., Schattner, Mark A., Janjigian, Yelena Y., Ku, Geoffrey Y., Maron, Steven B., Schoder, Heiko, Larson, Steven M., Gönen, Mithat, Datta, Jashodeep, Coit, Daniel G., Brennan, Murray F., and Strong, Vivian E.

Subjects
STOMACH cancer, OVERALL survival, RECTUS femoris muscles, POSITRON emission tomography computed tomography, LIVER, CANCER patients
Abstract

Background: PET–CT-based patient metabolic profiling is a novel concept to incorporate patient-specific metabolism into gastric cancer care. Methods: Staging PET–CTs, demographics, and clinicopathologic variables of gastric cancer patients were obtained from a prospectively maintained institutional database. PET–CT avidity was measured in tumor, liver, spleen, four paired muscles, and two paired fat areas in each patient. The liver to rectus femoris (LRF) ratio was defined as the ratio of SUVmean of liver to the average SUVmean of the bilateral rectus femoris muscles. Kaplan–Meier and Cox-proportional hazards models were used to identify the impact of LRF ratio on OS. Results: Two hundred and one patients with distal gastroesophageal (48%) or gastric (52%) adenocarcinoma were included. Median age was 65 years, and 146 (73%) were male. On univariate analysis, rectus femoris PET–CT avidity and LRF ratio were significantly associated with overall survival (p < 0.05). LRF ratio was significantly higher in males, early-stage cancer, patients with an ECOG 0 or 1 performance status, patients with albumin > 3.5 mg/dL, and those with moderately differentiated tumor histology. In multivariable regression, gastric cancer stage, albumin, and LRF ratio were significant independent predictors of overall survival (LRF ratio HR = 0.73 (0.56–0.96); p = 0.024). Survival curves showed that the prognostic impact of LRF was associated with metastatic gastric cancer (p = 0.009). Conclusions: Elevated LRF ratio, a patient-specific PET–CT-based metabolic parameter, was independently associated with an improvement in OS in patients with metastatic gastric cancer. With prospective validation, LRF ratio may be a useful, host-specific metabolic parameter for prognostication in gastric cancer. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

50. EDGE-Gastric Arm A1: Phase 2 study of domvanalimab, zimberelimab, and FOLFOX in first-line (1L) advanced gastroesophageal cancer.

Author

Janjigian, Yelena Y., primary, Oh, Do-Youn, additional, Pelster, Meredith, additional, Wainberg, Zev A., additional, Sison, Edward Allan R., additional, Scott, Jennifer R., additional, Ronayne, Jack, additional, Wishengrad, Dana, additional, Rhee, Joon, additional, Nuyten, Dimitry S. A., additional, and Rha, Sun Young, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results